AAAAAA
Results:
1-23
|
Results: 23
Authors:
DIERAS V
MISSET JL
BOURGEOIS H
BOZEC L
GRUIA G
CVITKOVIC E
AUSSEL P
RIVA A
AZLI N
POUILLART P
Citation: V. Dieras et al., DOCETAXEL (TAXOTERE(TM)) (T) AND DOXORUBICIN (A) AS 1ST LINE CT OF METASTATIC BREAST-CANCER (MBC) - HIGH-ACTIVITY AND LACK OF CARDIOTOXICITY AFTER 29-MONTH FOLLOW-UP, Annals of oncology, 9, 1998, pp. 79-79
Authors:
ANTOINE EC
CHOLLET P
MONFARDINI S
SORIO R
AMBROSINI G
BENHAMMOUDA A
MAZEN MF
RAMAZEILLES C
AZLI N
KHAYAT D
Citation: Ec. Antoine et al., SEQUENTIAL ADMINISTRATION OF DOCETAXEL (D) (TAXOTERE(TM)) FOLLOWED BYAC IN FIRST LINE METASTATIC BREAST-CANCER (MBC) PATIENTS (PTS) - FINAL RESULTS, Annals of oncology, 9, 1998, pp. 91-91
Authors:
MISSET JL
NABHOLTZ JM
DIERAS V
NOEL D
PATERSON A
ALTWEIGERI T
BOZEC L
RIVA A
AZLI N
POUILLART P
Citation: Jl. Misset et al., LONG-TERM FOLLOW-UP IN UNTREATED METASTATIC BREAST-CANCER (MBC) PTS TREATED WITH DOCETAXEL (TAXOTERE(TM)) (T) IN COMBINATION WITH DOXORUBICIN (A) - RESULTS OF 2 STUDIES, Annals of oncology, 9, 1998, pp. 119-119
Authors:
FANDI A
TAAMMA A
AZLI N
BACHOUCHI M
YANES B
ARMAND JP
CVITKOVIC E
Citation: A. Fandi et al., PALLIATIVE TREATMENT WITH LOW-DOSE CONTINUOUS-INFUSION 5-FLUOROURACILIN RECURRENT AND OR METASTATIC UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA TYPE/, Head & neck, 19(1), 1997, pp. 41-47
Authors:
DELECROIX V
FUMOLEAU P
PERROCHEAU G
AZLI N
FETY R
PRIOU F
MAUGARD C
RIVA A
LEMEVEL B
Citation: V. Delecroix et al., ANTHRACYCLINE AS 2ND LINE CHEMOTHERAPY (CT) FOR METASTATIC BREAST-CANCER (MBC) PATIENTS PREVIOUSLY TREATED WITH TAXOTERE (TXT), European journal of cancer, 33, 1997, pp. 666-666
Authors:
CIULEANU TE
CHAHINE A
TODOR N
MONNET I
AZLI N
VOISIN S
RIGGI M
SALTIEL JC
ARMAND JP
RUFFIE P
DECREMOUX H
CVITKOVIC E
Citation: Te. Ciuleanu et al., NEOADJUVANT CISPLATIN-VINDESINE VINORELBINE BASED COMBINATION CHEMOTHERAPY (CT) FOR STAGE-III NONSMALL CELL LUNG-CANCER (NSCLC)/, European journal of cancer, 33, 1997, pp. 1056-1056
Authors:
DIERAS V
FUMOLEAU P
KALLA S
MISSET JL
AZLI N
POUILLART P
Citation: V. Dieras et al., DOCETAXEL IN COMBINATION WITH DOXORUBICIN OR VINORELBINE, European journal of cancer, 33, 1997, pp. 20-22
Authors:
DIERAS V
FUMOLEAU P
BOURGEOIS H
MISSET JL
AZLI N
POUILLART P
Citation: V. Dieras et al., TAXOIDS IN COMBINATION CHEMOTHERAPY FOR METASTATIC BREAST-CANCER, Anti-cancer drugs, 7, 1996, pp. 47-52
Authors:
FUMOLEAU P
CHEVALLIER B
KERBRAT P
KRAKOWSKI Y
MISSET JL
MAUGARDLOUBOUTIN C
DIERAS V
AZLI N
BOUGON N
RIVA A
ROCHE H
Citation: P. Fumoleau et al., A MULTICENTER PHASE-II STUDY OF THE EFFICACY AND SAFETY OF DOCETAXEL AS FIRST-LINE TREATMENT OF ADVANCED BREAST-CANCER - REPORT OF THE CLINICAL SCREENING GROUP OF THE EORTC, Annals of oncology, 7(2), 1996, pp. 165-171
Authors:
CVITKOVIC E
ESCHWEGE F
RAHAL M",DOSEN,"MERSIC Z
KRAJINA Z
ARMAND JP
BOUHRIS J
TUBIANAMATHIEU M
FOUNTZILAS G
KOSMIDIS PA
PRASAD U
GANESAN S
ELGUEDDARI B
BACHOUCHI M
MANSOURI A
OLIVEIRA J
RAPOSO J
WIERZBICKI R
LIANES P
PENA C
ONAT H
ALTUN M
BENHAMOU E
DUCOURTIEUX M
AZLI N
FANDI A
TAAMMA A
BOSQ J
KLIJANIENKO J
SIGAL R
HONG WK
VOKES EE
CLARK JR
LEFLOCH O
BERNIER J
Citation: E. Cvitkovic et al., PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING NEOADJUVANT CHEMOTHERAPY (CISPLATIN, EPIRUBICIN, BLEOMYCIN) PLUS RADIOTHERAPY VS RADIOTHERAPY ALONE IN STAGE-IV (GREATER-THAN-OR-EQUAL-TO-N2, M0) UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA - A POSITIVE EFFECT ON PROGRESSION-FREESURVIVAL, International journal of radiation oncology, biology, physics, 35(3), 1996, pp. 463-469
Authors:
BENSMAINE MEA
AZLI N
DOMENGE C
ARMAND JP
CVITKOVIC E
Citation: Mea. Bensmaine et al., PHASE I-II TRIAL OF RECOMBINANT INTERFERON-ALPHA-2B WITH CISPLATIN AND 5-FLUOROURACIL IN RECURRENT AND OR METASTATIC CARCINOMA OF HEAD AND NECK/, American journal of clinical oncology, 19(3), 1996, pp. 249-254
Authors:
DIERAS V
CHEVALLIER B
KERBRAT P
KRAKOWSKI I
ROCHE H
MISSET JL
LENTZ MA
AZLI N
MURAWSKY M
RIVA A
POUILLART P
FUMOLEAU P
Citation: V. Dieras et al., A MULTICENTER PHASE-II STUDY OF DOCETAXEL 75 MG M(-2) AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH ADVANCED BREAST-CANCER - REPORT OF THE CLINICAL SCREENING GROUP OF THE EORTC, British Journal of Cancer, 74(4), 1996, pp. 650-656
Authors:
FANDI A
TAAMMA A
AZLI N
BACHOUCHI M
YANES B
CVITKOVIC E
ARMAND J
Citation: A. Fandi et al., 5-FLUOROURACIL (FU) BLEOMYCIN (B), EPIRUBICIN (E), CISPLATIN (P) IN LOCALLY ADVANCED (LA), RECURRENT AND OR IMETASTATIC (REC/MTS) UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE (UNCT) PRELIMINARY ACTIVITY TOXICITY REPORT/, European journal of cancer, 31A, 1995, pp. 401-401
Authors:
DIERAS V
GRUIA G
POUILLART P
CVITKOVIC E
GENTIN M
AZLI N
RIVA A
MISSET JL
Citation: V. Dieras et al., A PHASE-I STUDY OF THE COMBINATION OF DOCETAXEL (D) AND ADRIAMICIN (AD) IN FIRST-LINE CT TREATMENT OF METASTATIC BREAST-CANCER (MBC), European journal of cancer, 31A, 1995, pp. 935-935
Authors:
FUMOLEAU P
DELECROIX V
GENTIN M
PERROCHEAU G
LOUBOUTIN C
FETY R
AZLI N
RIVA A
Citation: P. Fumoleau et al., DOCETAXEL (D) IN COMBINATION WITH VINORELBINE (V) AS FIRST LINE CT INPTS WITH MBC - PHASE-I DOSE-FINDING STUDY, European journal of cancer, 31A, 1995, pp. 938-938
Authors:
LOUBOUTIN JP
MAUGARDLOUBOUTIN C
PERROCHEAU G
GENTIN M
DELECROIX V
AZLI N
FUMOLEAU P
Citation: Jp. Louboutin et al., AN EVALUATION OF THE NEUROTOXICITY OF A PHASE-I DOSE-FINDING STUDY OFDOCETAXEL (D) IN COMBINATION WITH VINORELBIN (V), European journal of cancer, 31A, 1995, pp. 970-970
Authors:
CHEVALLIER B
FUMOLEAU P
KERBRAT P
DIERAS V
ROCHE H
KRAKOWSKI I
AZLI N
BAYSSAS M
LENTZ MA
VANGLABBEKE M
Citation: B. Chevallier et al., DOCETAXEL IS A MAJOR CYTOTOXIC DRUG FOR THE TREATMENT OF ADVANCED BREAST-CANCER - A PHASE-II TRIAL OF THE CLINICAL SCREENING COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER, Journal of clinical oncology, 13(2), 1995, pp. 314-322
Authors:
FUMOLEAU P
CHEVALLIER B
KERBRAT P
DIERAS V
AZLI N
BAYSSAS M
VANGLABBEKE M
Citation: P. Fumoleau et al., CURRENT STATUS OF TAXOTERE(R) (DOCETAXEL) AS A NEW TREATMENT IN BREAST-CANCER, Breast cancer research and treatment, 33(1), 1995, pp. 39-46
Authors:
FANDI A
ALTUN M
AZLI N
ARMAND JP
CVITKOVIC E
Citation: A. Fandi et al., NASOPHARYNGEAL CANCER - EPIDEMIOLOGY, STAGING, AND TREATMENT, Seminars in oncology, 21(3), 1994, pp. 382-397
Authors:
FANDI A
YANES B
TAAMMA A
AZLI N
ARMAND JP
DUPUIS O
ESCHWEGE F
SCHWAAB G
CVITKOVIC E
Citation: A. Fandi et al., UNDIFFERENTIATED CARCINOMA OF THE NASOPHA RYNX - EPIDEMIOLOGIC, CLINICAL AND THERAPEUTIC ASPECTS, Bulletin du cancer, 81(7), 1994, pp. 571-586
Authors:
RIGGI M
CVITKOVIC E
DECREMOUX H
RUFFIE P
MONNET I
VOISIN S
VILLALOBOS W
AZLI N
SALTIEL JC
Citation: M. Riggi et al., CISPLATIN AND CONTINUOUS-INFUSION VINDESINE AND 5-FLUOROURACIL IN NON-SMALL-CELL LUNG-CANCER (NSCLC) (ATTIT-002), European journal of cancer, 29A(13), 1993, pp. 1914-1915
Authors:
CVITKOVIC E
BACHOUCHI M
BOUSSEN H
BUSSON P
ROUSSELET G
MAHJOUBI R
FLORES P
TURSZ T
ARMAND JP
AZLI N
Citation: E. Cvitkovic et al., LEUKEMOID REACTION, BONE-MARROW INVASION, FEVER OF UNKNOWN ORIGIN, AND METASTATIC PATTERN IN THE NATURAL-HISTORY OF ADVANCED UNDIFFERENTIATED CARCINOMA OF NASOPHARYNGEAL TYPE - A REVIEW OF 255 CONSECUTIVE CASES, Journal of clinical oncology, 11(12), 1993, pp. 2434-2442
Authors:
ROUSSELET G
BACHOUCHI M
BUSSON P
DEVATHAIRE F
WAKASUGI H
SCHWAAB G
AZLI N
ARMAND JP
CVITKOVIC E
TURSZ T
Citation: G. Rousselet et al., CLINICAL IMPLICATIONS OF THE SERUM LEVEL OF CD23 IN PATIENTS WITH UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA, Journal of clinical oncology, 11(11), 1993, pp. 2143-2149
Risultati:
1-23
|